Introduction
MVC is the exclusive partner of GC pharma for FLU Quadrivalent in Taiwan. This partnership supports MVC's strategy to provide people with prophylactic treatments against infectious diseases.
There are four types of influenza viruses, A, B, C, and D. Only influenza A and B cause seasonal influenza epidemics with mild to severe illness. Serious disease may result in hospitalization or death. Influenza vaccination is the most effective way to prevent influenza.
Features
- MVC cooperates with GC Pharma, a major Korean vaccine manufacturer, which is the largest seasonal influenza vaccine supplier to the international organization PAHO.
- World's 2nd WHO prequalified seasonal Influenza vaccine quadrivalent which is designed to protect against four different flu viruses.
Progress
- MVC has completed phase III clinical trial for FLU Quadrivalent.
- MVC has submitted a New Drug Application (NDA) to the Taiwan FDA.
FLU Quadrivalent
R&D/Preclinical
Phase I
Phase II
Phase III
Marketed